// App-Quantinova.ai

2116 : Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Researchers

Presenter

  • David G. Maloney

Principal Investigators

  • John Kuruvilla

  • Christopher P Fox

  • Guillaume Cartron

  • Daniel Li

  • Jens Hasskarl

  • Ashley Bonner

  • Yixie Zhang

  • Fei Fei Liu

Medical Centers

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Centre Hospitalier Universitaire, Montpellier, Montpellier, France

  • Juno Therapeutics, a Bristol-Myers Squibb company,Seattle,United States

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Eversana,Burlington,Canada

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

  • Canada

  • United Kingdom

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cytokine release syndrome

  • Hypogammaglobulinaemia

  • B cell lymphomas

  • Encephalopathy

  • Lymphomas

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • Lisocabtagene maraleucel

  • Axicabtagene ciloleucel

  • tisagenlecleucel-t

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • NCT02631044

  • NCT02348216

  • NCT02445248

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved